AKYLA/ Financials
MarketsScreenerFinancialsResearchChat
Equity / PHARMACEUTICAL PREPARATIONS
Talphera, Inc. Common Stock
XNAS · usd
SIC 2834 · PHARMACEUTICAL PREPARATIONS
FIGI BBG001TFZCK5
1.08▲ 0.03 (2.86%)
As of 2026-10-23
Price / Volume
Valuation
Market Cap
Enterprise Value
—
Trailing P/E
—
Price / Sales
EV / Revenue
—
EV / EBITDA
—
Financial Highlights
Revenue (TTM)
Net Income (TTM)
EBITDA
—
Diluted EPS (TTM)
EBITDA Margin
—
Net Debt
—
Trading Information
Previous Close
1.05
Day's Range
1.05 – 1.08
52-Week Range
0.69 – 1.57
Volume
76.7K
Avg Volume
119.7K
Share Statistics
Shares Outstanding
Employees
12
Exchange
XNAS
Listed
2011-02-11
Share count as of August 6, 2026

Talphera, Inc. Common Stock (TLPH) Financial Statements

View
Income Statement
Detail
Standard
Period
Quarterly
Loading Income Statement…
Key questions about Talphera, Inc. Common Stock (TLPH)
What is Talphera, Inc. Common Stock's Market Cap?
Talphera, Inc. Common Stock's Market Cap is $56.1M, based on as-reported figures from SEC (XBRL) filings.
What is Talphera, Inc. Common Stock's Price / Sales?
Talphera, Inc. Common Stock's Price / Sales is 56058.3×, based on as-reported figures from SEC (XBRL) filings.
What is Talphera, Inc. Common Stock's Revenue (TTM)?
Talphera, Inc. Common Stock's Revenue (TTM) is $1.0K, based on as-reported figures from SEC (XBRL) filings.
What is Talphera, Inc. Common Stock's Net Income (TTM)?
Talphera, Inc. Common Stock's Net Income (TTM) is -$15.1M, based on as-reported figures from SEC (XBRL) filings.
What is Talphera, Inc. Common Stock's Diluted EPS (TTM)?
Talphera, Inc. Common Stock's Diluted EPS (TTM) is -0.29, based on as-reported figures from SEC (XBRL) filings.
Akyla / Financials · TLPHAs-filed SEC (XBRL) data
Showing the most recent year. Subscribe for full statement history.
Income Statement(in USD, except per-share data)
Source: Akyla.ai
Line ItemJun 30, 2026Mar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022
Revenue
YoY growth—-100.0%——
Operating costs and expenses:
Research and development
Selling, general and administrative
Total operating costs and expenses
% of revenue———342300.0%
Loss from operations
% of revenue———-342200.0%
Other (expense) income, net:
Interest income and other income, net
(Loss) gain on change in fair value of warrant liability
Total other (expense) income, net
Net loss from continuing operations
Net loss
% of revenue———-443600.0%
Net loss per share attributable to stockholders:
Basic and diluted loss per share (in dollars per share)